AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02134652 — intervention group
Intervention type: OTHER
Intervention: diagnostic bedside ultrasound
Description: Patients enrolled in this study will undergo bedside ultrasound during their initial presentation to the emergency department. Ultrasound imaging protocols include the following:~* FAST Exam - Standard images will be obtained using the abdominal transducer. Images include the following: 1) sub-xyphoid 2)right upper quadrant (with right thorax) 3)left upper quadrant (with left thorax) and 4) suprapubic~* Right Upper Quadrant Exam - Standard images will be obtained using the abdominal transducer. Images include the following: 1) Long axis of the gallbladder 2) Transverse axis of the gallbladder fundus 3) Transverse axis of the gallbladder body and 4) Transverse axis of the gallbladder neck.
Study NCT02996864 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Healthy Detours App
Description: The app features:~* Immediate and relevant feedback at the point of decision-making to reinforce healthy lifestyle behaviors within a population making crucial lifestyle choices.~* User-centered and location-specific tailored information to provide users with information to improve future decision-making through activity tracking.~* Multiple health-tracking features (i.e., diet and PA tracking, and accelerometry for PA and sleep) that will aid in self-monitoring.
Study NCT02996864 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Fat Secret App
Description: Freely available app for weight loss and nutrition. Includes food and exercise diaries; calorie counting.
Study NCT00589953 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erythropoietin
Description: 5 of first 10 subjects (Group 1): 400 units/kg/dose once daily for 7 days 5 of next 10 subjects (Group 2): 800 units/kg/dose once daily for 7 days 20 of next 30 subjects (Group 3): 1000 units/kg/dose once daily for 7 days administered i.v. over 1 hour.~The volume of the study drug will be 1 mL in a 1 mL Tuberculin syringe to be administered over 1 hour.
Study NCT03637010 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Breakfast in the Classroom
Description: For all breakfasts, the students will use the 'grab and go' approach from hallway kiosks. The students will take the breakfasts back to their respective classroom and consume them there.
Study NCT00589953 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline placebo
Description: Saline vehicle at a volume of 1 mL given over 1 hour intravenously once a day for the first seven days of life.
Study NCT02164227 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Respiratory pattern
Study NCT02117375 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: spinal cord MRI follow-up
Description: Evaluation : focal lesions (number, volume, localisation), atrophy, parameters from Diffusion Tensor Imaging and parameters from Magnetization Transfer Ratio
Study NCT02117375 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: clinical follow-up
Description: Relapses, treatments, global disability,walking performance, upper limbs motor performance, sphincter disturbances and walking difficulty
Study NCT02117375 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: brain MRI follow-up
Study NCT01074164 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard-of-care treatment for AD
Description: Subjects will receive standard of care treatment for atopic dermatitis, including moisturizers and topical corticosteroids, per their dermatologist.
Study NCT01074164 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Accu-patch pellet
Description: The accu-patch pellets will be applied to the LI11 pressure point, located on the left arm lateral to the antecubital fossae, for 10 minutes, 3 times a week for 1 month.
Study NCT05404061 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Gut hormones
Description: Their first visit will act as an acclimatisation visit and participants will be infused subcutaneously with a triple gut hormone infusion (GLP-1, PYY and OXM). This will not only allow us to acclimatise the study volunteer to the study visits, but also allow us to test for subject tolerability of the gut hormones.~For the next two visits participants will be randomised in a single-blinded fashion to a subcutaneous infusion of either:~1. 0.9% saline,~2. GLP-1
Study NCT02993003 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Nasopharyngeal probe
Description: nasopharyngeal probe insertion
Study NCT00615277 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Omega-3 fatty acids
Description: 600 mg EPA 120mg DHA daily, 16 weeks
Study NCT00615277 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Omega-3 fatty acids
Description: 600 mg EPA 120mg DHA daily, 16 weeks
Study NCT03547713 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social feedback
Description: Social feedback regarding performance of a public speech is delivered to participants
Study NCT03547713 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-referential paradigm
Description: Exposure to traits varying in valence (positive vs. negative) and social domain (power vs. affiliation)
Study NCT03547713 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reward vs. punishment task
Description: Reception of monetary gains vs. losses
Study NCT03547713 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Emotional reactivity task
Description: Exposure to emotional faces vs. shapes
Study NCT04019743 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-330 16/10mg Tab. 1T and D086 Tab. 1T
Description: single oral administration under fasting condition
Study NCT04019743 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-333 16/10/40mg formulation 1 Tab. 1T
Description: single oral administration under fasting condition
Study NCT01982955 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tepotinib
Description: Tepotinib was administered at a dose range of 300 or 500 milligram (mg) (Phase 1b) and the recommended phase II dose (RP2D) determined in the Phase 1b in Phase II orally once daily over a 21-day cycle until progressive disease, intolerable toxicity, participants withdrawal from treatment. RP2D was determined as per safety monitoring committee (SMC) discretion.
Study NCT01982955 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gefitinib
Description: Gefitinib was administered at a dose of 250 mg orally as once daily over a 21-day cycle until progressive disease, intolerable toxicity, participants withdrawal from treatment.
Study NCT04019743 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-333 16/10/40mg formulation 2 Tab. 1T
Description: single oral administration under fasting condition
Study NCT03071172 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant Human Choriogonadotropin alfa Solution for Injection
Description: Drugs for IVF-ET (in vitro fertilization and embryo transfer).
Study NCT03071172 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Progesterone Soft Capsules
Description: Drugs for IVF-ET (in vitro fertilization and embryo transfer).
Study NCT02477995 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DTaP Vaccine A
Description: Adsorption tetanus-diphtheria-acellular pertussis (DTaP) Vaccine A(Bejing minhai Biological Co., LTD) of 0.5ml, three doses, 28 days interval
Study NCT02477995 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: DTaP Vaccine B
Description: Adsorption tetanus-diphtheria-acellular pertussis (DTaP) Vaccine B(Changchun changsheng Biological Co., LTD ) of 0.5ml in 600 infants aged 3-5months on day 0, 28, 56.
Study NCT03656419 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: photodynamic therapy
Description: aPDT with methylene blue and red led irradiation.
Study NCT03656419 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Tongue scraper
Description: Tongue scraper 10 times from de back to the top.
Study NCT03656419 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tongue scraper
Description: Tongue scraper 10 times from de back to the top.
Study NCT03257631 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Description: : Subjects will be administered pomalidomide on Days 1 to 21, followed by a 7-day rest period, of each 28-day treatment cycle and will continue treatment for up to 24 cycles or until disease progression, withdrawal of consent/assent or unresolved toxicities as described in the protocol.
Study NCT03257631 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Description: Pomalidomide will be provided as gelatin capsules and as an oral suspension. The starting dose will be 2.6 mg/m²/day, administered on Days 1 to 21, followed by a 7-day rest period, of each 28-day treatment cycle.
Study NCT04172441 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dasiglucagon
Description: Glucagon analogue
Study NCT04172441 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo for dasiglucagon
Study NCT00741481 — intervention group
Intervention type: PROCEDURE
Intervention: FDG-PET imaging
Description: FDG-PET imaging at D0 and D14 of first course of a new chemotherapy for advanced colorectal cancer
Study NCT03232385 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MR-US Fusion Arm
Description: Use of Clear Guide SCENERGY for MR-US fusion guidance
Study NCT03232385 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Renal Biopsy or Ablation
Description: Standard of Care
Study NCT02088983 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: CDP-Choline
Description: Capsule
Study NCT02088983 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Cellulose
Description: Capsule
Study NCT01340157 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fexinidazole
Description: Single oral dose of 1200mg fexinidazole consisting of 2 tablets dosed at 600mg per tablet.
Study NCT03468907 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telbivudine 600mg
Description: Pregnant mothers who opted for antiviral therapy would start on oral LDT 600 mg daily between gestational weeks 24 and 28.
Study NCT03468907 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate 300mg
Description: Pregnant mothers who opted for antiviral therapy would start on oral TDF 300 mg daily between gestational weeks 24 and 28.
Study NCT01810666 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Factor VIII (Kogenate FS, BAY14-2222)
Description: Participants received Recombinant Factor VIII (Rec. factor VIII) on-demand treatment for 12 weeks followed by a 12 weeks prophylaxis treatment phase. The dose and mode of prophylaxis treatment was 25 IU/Kg, 3 times/per week. The dose in on-demand treatment was decided by physician according to the package insert or the current standard of care.
Study NCT04398758 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SanaCutan Basiscreme
Description: In this study, the SanaCutan Basiscreme will be used as a cream for twice daily application on the whole body (eyes and mucous membranes have to be omitted) for a duration of 6 months (main phase) or 12 months (main + follow-up phase) or less (if the child develops atopic dermatitis).
Study NCT00394212 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transoral Suturing
Description: suturing of anastomosis
Study NCT00394212 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Endoscopy
Description: suturing not performed
Study NCT00978328 — intervention group
Intervention type: DRUG
Intervention: oxycodone immediate release (OXYRX)
Description: Characteristics of pts. receiving prescription medications containing OXYRX
Study NCT01267396 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sertraline
Description: Sertraline Hydrochloride Tablets 100 mg
Study NCT01267396 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sertraline
Description: Sertraline Hydrochloride Tablets 100 mg
Study NCT03606681 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcium Hydroxide
Description: After cleaning the caries with partial removal (non-exposed pulp), cavity disinfected with sodium hypochlorite then indirect pulp capping agent was applied to cavity and restoration was finished in the same session.
Study NCT03606681 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcium Hydroxide
Description: After cleaning the caries with partial removal (non-exposed pulp), cavity disinfected with sodium hypochlorite then indirect pulp capping agent was applied to cavity and restoration was finished in the same session.
Study NCT03606681 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mineral Trioxide Aggregate
Description: After cleaning the caries with partial removal (non-exposed pulp), cavity disinfected with sodium hypochlorite then indirect pulp capping agent was applied to cavity and restoration was finished in in the same session.
Study NCT03606681 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mineral Trioxide Aggregate
Description: After cleaning the caries with partial removal (non-exposed pulp), cavity disinfected with sodium hypochlorite then indirect pulp capping agent was applied to cavity and restoration was finished in in the same session.
Study NCT03606681 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TheraCal LC
Description: After cleaning the caries with partial removal (non-exposed pulp), cavity disinfected with sodium hypochlorite then indirect pulp capping agent was applied to cavity (2 milimeter layer) and polymerized and restoration was finished in in the same session.
Study NCT03606681 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TheraCal LC
Description: After cleaning the caries with partial removal (non-exposed pulp), cavity disinfected with sodium hypochlorite then indirect pulp capping agent was applied to cavity (2 milimeter layer) and polymerized and restoration was finished in in the same session.
Study NCT03488316 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Carie removal
Description: Carie removal with a low speed handpiece
Study NCT03488316 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Absolute isolation
Description: Absolute isolation with rubber dam
Study NCT03488316 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Manipulation of the temporary filling material based on Calcium Hydroxide
Description: Manipulation of the temporary material based on Calcium Hydroxide according to the manufacturer's recommendations.
Study NCT03488316 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Manipulation of the temporary filling material based on Mineral trioxide aggregate
Description: Manipulation of the temporary material based on Mineral trioxide aggregate according to the manufacturer's recommendations.
Study NCT03488316 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Material insertion on the root canal
Description: Material insertion on the root canal according to the manufacturer's recommendations
Study NCT03488316 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Material re-insertion on the root canal accordging to the infection needs.
Description: Material re-insertion on the root canal according to the manufacturer's recommendations
Study NCT03488316 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Definiteve canal root obturation
Description: Definiteve canal root obturation with gutta-percha and definitive cement.
Study NCT03488316 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Definitve restoration
Description: Definitve restoration confecction.
Study NCT03521479 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Squaric Acid Dibutyl Ester
Description: Repeat topical application of 2% and 0.5% squaric acid dibutyl ester (SADBE) in subjects with frequent herpes labialis (4 or more episodes in the previous 12 months).
Study NCT00891358 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prevention Empowerment Intervention for Young Women
Description: Using three intervention sites, focus groups will guide the development of the intervention's framework and content areas. An initial list of content areas and potential activities for presentation to the focus groups will be developed by the protocol team by reviewing existing HIV prevention interventions that have been implemented with adolescents and young adults, as well as interventions that have targeted HIV+ populations.~The three focus groups will be convened (1 per selected ATN site) with young women living with HIV to solicit information on their intervention needs.
Study NCT03240133 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BCX7353
Description: oral liquid formulation
Study NCT03240133 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral liquid formulation to match BCX7353
Study NCT00469482 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sedation,RASS Targeted plus BIS Monitoring
Description: Providing patient sedation utilizing standard of care methods (RASS) plus BIS monitoring
Study NCT00469482 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sedation, RASS Targeted
Description: Patient sedation utilizing standard of care methods (RASS targeted)
Study NCT03239470 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cohort 1: 1.0 x 10^8 PolyTregs
Description: Each participant will receive a target cell dose of 1.0 x 10\^8 polyclonal Tregs.
Study NCT03239470 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cohort 2: 2.5x10^8 PolyTregs
Description: Each participant will receive a target cell dose of 2.5x10\^8 polyclonal Tregs.
Study NCT02755376 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cartistem(TM)
Description: ACL reconstruction and injection of Cartstem(TM), human cord blood derived mesenchymal stem cell under arthroscopy.
Study NCT02755376 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: hyaluronic acid
Description: ACL reconstruction and injection of hyaluronic acid under arthroscopy.
Study NCT02755376 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ACL reconstruction only
Description: ACL reconstruction only without any injection under arthroscopy
Study NCT02755376 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ACL reconstruction only
Description: ACL reconstruction only without any injection under arthroscopy
Study NCT02511470 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Metronome on
Description: Metronome on during participants performance of CPR on a pediatric manikin
Study NCT02511470 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Metronome off
Description: Metronome off during participants performance of CPR on a pediatric manikin
Study NCT01510119 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Study NCT01510119 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RAD001
Study NCT03721419 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High Flow High Humidity device
Description: High Flow High Humidity device has a flow generator built into the body of unit and can deliver flows between 10 to 60 Liters per minute (LPM) with oxygen bled in as needed in order to deliver specified Fraction of inspired Oxygen (FiO2)
Study NCT03721419 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Low Flow High Humidity device
Description: Standard high humidity trach collar utilizing venturi device bleed in
Study NCT03521479 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Squaric Acid Dibutyl Ester
Description: Repeat topical application of 2% and 0.5% squaric acid dibutyl ester (SADBE) in subjects with frequent herpes labialis (4 or more episodes in the previous 12 months).
Study NCT01023581 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alogliptin
Description: Alogliptin tablets.
Study NCT01023581 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin capsules
Study NCT01023581 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Metformin capsules
Study NCT01023581 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alogliptin Placebo
Description: Alogliptin placebo-matching tablets.
Study NCT01023581 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Alogliptin Placebo
Description: Alogliptin placebo-matching tablets.
Study NCT01023581 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin Placebo
Description: Metformin placebo-matching capsules.
Study NCT01023581 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metformin Placebo
Description: Metformin placebo-matching capsules.
Study NCT01748253 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Telmisartan-amlodipine tablet administration group (morning)
Description: Oral-administration of one telmisartan-amlodipine tablet once a day upon morning for 12 weeks
Study NCT01748253 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Telmisartan-amlodipine tablet administration group (bedtime)
Description: Oral-administration of one telmisartan-amlodipine tablet once a day at bedtime for 12 weeks